pirarubicin Report issue

Small molecule Experimental
AACT ChEMBL DrugBank Drug Central KEGG MeSH PubChem

Active Ingredient History

NOW
  • Now
Pirarubicin (INN) is an anthracycline drug. An analogue of the anthracycline antineoplastic antibiotic doxorubicin. Pirarubicin intercalates into DNA and interacts with topoisomerase II, thereby inhibiting DNA replication and repair and RNA and protein synthesis. This agent is less cardiotoxic than doxorubicin and exhibits activity against some doxorubicin-resistant cell lines.   Wikipedia

Chemistry

  • SMILES: COc1cccc2C(=O)c3c(O)c4C[C@](O)(C[C@H](O[C@H]5C[C@H](N)[C@H](O[C@H]6CCCCO6)[C@H](C)O5)c4c(O)c3C(=O)c12)C(=O)CO
  • InChIKey: KMSKQZKKOZQFFG-HSUXVGOQSA-N
  • Mol. Mass: 627.64
  • ALogP: 1.55
  • ChEMBL Molecule:
    pirarubicin  
More Chemistry

Pharmacology

Alternative names

4'-o-tetrahydropyranyladriamycin | 4'-o-tetrahydropyranyldoxorubicin | 4'-o-tetrapyranyldoxorubicin | 5,12-naphthacenedione, 10-((3-amino-2,3,6-trideoxy-4-o-(tetrahydro-2h-pyran-2-yl)-alpha-l-lyxo-hexopyranosyl)oxy)-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-, (8s-cis)- | adriamycin, tetrahydropyranyl | aventis brand of pirarubicin | pinorubicin | pirarubicin | pirarubicin hydrochloride | thepirubicin | theprubicin | théprubicine | therarubicin | thp-adm | thp-adriamycin | thp-dox | thp-doxorubicin

Organizations (23)

Research & Development (23)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Marketing (0)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Indications (20)

Approved Indications (1)


 

Neoplasms

Experimental Indications - Clinical Trial Phases 1-4 (19)


 

Administration, Intravesical (Phase 2)

Breast Neoplasms (Phase 4)

Carcinoma, Hepatocellular (Phase 3)

Carcinoma, Transitional Cell (Phase 2)

Drug-Related Side Effects and Adverse Reactions (Phase 2/Phase 3)

Enteropathy-Associated T-Cell Lymphoma (Phase 4)

Lymphoma, B-Cell (Phase 4)

Lymphoma, Large-Cell, Anaplastic (Phase 4)

Lymphoma, T-Cell (Phase 4)

Medulloblastoma (Phase 4)

Multiple Myeloma (Phase 4)

Neoplasms, Germ Cell and Embryonal (Phase 4)

Nephroureterectomy (Phase 2)

Precursor Cell Lymphoblastic Leukemia-Lymphoma (Phase 2)

Progression-Free Survival (Phase 2/Phase 3)

Sarcoma (Phase 2)

Triple Negative Breast Neoplasms (Phase 2)

Urinary Bladder Diseases (Phase 2)

Wilms Tumor (Phase 4)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 23
  • # of Trial Organizations: 23

Trials by Phase

Trial Phase Start Date Organizations Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue